Former Leo Pharma candidate heads into big study as FDA fast-tracks assessment

Union Therapeutics is preparing a large-scale phase IIb trial to test its candidate orismilast within atopic dermatitis. On Thursday, the FDA fast-tracked the drug, potentially saving the biotech company "several months" in a potential approval case processing, the company's CFO says.
Morten Boesen, CFO at Union Therapeutics. | Photo: Union Therapeutics
Morten Boesen, CFO at Union Therapeutics. | Photo: Union Therapeutics
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN AND CATHERINE BRETT

Acquiring drug candidate orismilast from Leo Pharma in summer of last year in a deal valued up to DKK 1.2bn (USD 186.4m) has turned out to be a good decision for Union Therapeutics.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading